These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 7615010)

  • 1. The type I interleukin-1 receptor acts in series with tumor necrosis factor (TNF) to induce arthritis in TNF-transgenic mice.
    Probert L; Plows D; Kontogeorgos G; Kollias G
    Eur J Immunol; 1995 Jun; 25(6):1794-7. PubMed ID: 7615010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Major role for interleukin 1 but not for tumor necrosis factor in early cartilage damage in immune complex arthritis in mice.
    Van Lent PL; Van De Loo FA; Holthuysen AE; Van Den Bersselaar LA; Vermeer H; Van Den Berg WB
    J Rheumatol; 1995 Dec; 22(12):2250-8. PubMed ID: 8835558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myelodysplasia and anemia of chronic disease in human tumor necrosis factor-alpha transgenic mice.
    Capocasale RJ; Makropoulos DA; Achuthanandam R; Stowell N; Quinn J; Rafferty PA; O'Brien J; Emmell E; Bugelski PJ
    Cytometry A; 2008 Feb; 73(2):148-59. PubMed ID: 18205195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A murine transmembrane tumor necrosis factor (TNF) transgene induces arthritis by cooperative p55/p75 TNF receptor signaling.
    Alexopoulou L; Pasparakis M; Kollias G
    Eur J Immunol; 1997 Oct; 27(10):2588-92. PubMed ID: 9368614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction.
    Zwerina J; Hayer S; Tohidast-Akrad M; Bergmeister H; Redlich K; Feige U; Dunstan C; Kollias G; Steiner G; Smolen J; Schett G
    Arthritis Rheum; 2004 Jan; 50(1):277-90. PubMed ID: 14730626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion.
    Lubberts E; Koenders MI; Oppers-Walgreen B; van den Bersselaar L; Coenen-de Roo CJ; Joosten LA; van den Berg WB
    Arthritis Rheum; 2004 Feb; 50(2):650-9. PubMed ID: 14872510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of the inflammatory cytokine network among TNF alpha, IL-1 beta, IL-1 receptor antagonist, and IL-8 in LPS-induced rabbit arthritis.
    Matsukawa A; Yoshimura T; Miyamoto K; Ohkawara S; Yoshinaga M
    Lab Invest; 1997 May; 76(5):629-38. PubMed ID: 9166282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute CD4+ T lymphocyte-dependent interleukin-1-driven arthritis selectively requires interleukin-2 and interleukin-4, joint macrophages, granulocyte-macrophage colony-stimulating factor, interleukin-6, and leukemia inhibitory factor.
    Lawlor KE; Wong PK; Campbell IK; van Rooijen N; Wicks IP
    Arthritis Rheum; 2005 Dec; 52(12):3749-54. PubMed ID: 16320325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The type II decoy receptor of IL-1 inhibits murine collagen-induced arthritis.
    Bessis N; Guéry L; Mantovani A; Vecchi A; Sims JE; Fradelizi D; Boissier MC
    Eur J Immunol; 2000 Mar; 30(3):867-75. PubMed ID: 10741403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of endogenous tumor necrosis factor alpha and interleukin 1 for experimental tumor growth and the development of cancer cachexia.
    Gelin J; Moldawer LL; Lönnroth C; Sherry B; Chizzonite R; Lundholm K
    Cancer Res; 1991 Jan; 51(1):415-21. PubMed ID: 1703040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNFalpha, anti-IL-1alpha/beta and IL-1Ra.
    Joosten LA; Helsen MM; van de Loo FA; van den Berg WB
    Arthritis Rheum; 2008 Feb; 58(2 Suppl):S110-22. PubMed ID: 18240201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic relapsing homologous collagen-induced arthritis in DBA/1 mice as a model for testing disease-modifying and remission-inducing therapies.
    Malfait AM; Williams RO; Malik AS; Maini RN; Feldmann M
    Arthritis Rheum; 2001 May; 44(5):1215-24. PubMed ID: 11352257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of pristane-induced arthritis, a murine model of chronic disease: response to antirheumatic agents, expression of joint cytokines, and immunopathology.
    Patten C; Bush K; Rioja I; Morgan R; Wooley P; Trill J; Life P
    Arthritis Rheum; 2004 Oct; 50(10):3334-45. PubMed ID: 15476226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arthritis induced with cartilage-specific antibodiesis IL-4-dependent.
    Nandakumar KS; Holmdahl R
    Eur J Immunol; 2006 Jun; 36(6):1608-18. PubMed ID: 16688680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined blockade of granulocyte-macrophage colony stimulating factor and interleukin 17 pathways potently suppresses chronic destructive arthritis in a tumour necrosis factor alpha-independent mouse model.
    Plater-Zyberk C; Joosten LA; Helsen MM; Koenders MI; Baeuerle PA; van den Berg WB
    Ann Rheum Dis; 2009 May; 68(5):721-8. PubMed ID: 18495731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathogenic role of interleukin-6 in the development of sepsis. Part II: Significance of anti-interleukin-6 and anti-soluble interleukin-6 receptor-alpha antibodies in a standardized murine contact burn model.
    Pallua N; Low JF; von Heimburg D
    Crit Care Med; 2003 May; 31(5):1495-501. PubMed ID: 12771624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Collagen-induced arthritis in TNF receptor-1-deficient mice: TNF receptor-2 can modulate arthritis in the absence of TNF receptor-1.
    Tada Y; Ho A; Koarada S; Morito F; Ushiyama O; Suzuki N; Kikuchi Y; Ohta A; Mak TW; Nagasawa K
    Clin Immunol; 2001 Jun; 99(3):325-33. PubMed ID: 11358427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-1 drives pathogenic Th17 cells during spontaneous arthritis in interleukin-1 receptor antagonist-deficient mice.
    Koenders MI; Devesa I; Marijnissen RJ; Abdollahi-Roodsaz S; Boots AM; Walgreen B; di Padova FE; Nicklin MJ; Joosten LA; van den Berg WB
    Arthritis Rheum; 2008 Nov; 58(11):3461-70. PubMed ID: 18975337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo.
    Axmann R; Böhm C; Krönke G; Zwerina J; Smolen J; Schett G
    Arthritis Rheum; 2009 Sep; 60(9):2747-56. PubMed ID: 19714627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endogenous interleukin-6, but not tumor necrosis factor alpha, contributes to the development of toll-like receptor 4/myeloid differentiation factor 88-mediated acute arthritis in mice.
    Kyo F; Futani H; Matsui K; Terada M; Adachi K; Nagata K; Sano H; Tateishi H; Tsutsui H; Nakanishi K
    Arthritis Rheum; 2005 Aug; 52(8):2530-40. PubMed ID: 16052598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.